Comparison of Bracing With Co-aptation Splinting for the Initial Treatment of Acute Humeral Shaft Fractures: The COBRAS Trials
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Abhishek Ganta, MD
- Phone Number: 718-206-6923
- Email: abhishek.ganta@nyulangone.org
Study Locations
-
-
New York
-
Garden City, New York, United States, 11530
- NYU Winthrop Hospital
-
New York, New York, United States, 10016
- NYU Langone Health
-
Queens, New York, United States, 11418
- Jamaica Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Presenting to an emergency room or ICARE in the participating centers with an acute humeral shaft fracture
- Age above 18 and skeletally mature
- Isolated Injury
- Treated non-operatively first 2 weeks
Exclusion Criteria:
- Open fractures
- Poly trauma
- Injuries deemed operative by attending surgeon
- Patients undergoing treatment for malignancy
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Coaptation Splint
|
Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus.
The forearm and wrist are then suspended in a cuff and collar.
|
|
Active Comparator: Sarmiento Brace
|
Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm.
The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score on Pain Visual Analogue Scale (VAS)
Time Frame: Week 1 post-treatment
|
The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain).
The patient is asked to mark their current pain level on the line.
The total range of score is 0 (no pain) to 10 (unbearable pain); the higher the pain, the greater the amount of pain.
|
Week 1 post-treatment
|
|
Score on Pain Visual Analogue Scale (VAS)
Time Frame: Week 2 post-treatment
|
The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain).
The patient is asked to mark their current pain level on the line.
The total range of score is 0 (no pain) to 10 (unbearable pain); the higher the pain, the greater the amount of pain.
|
Week 2 post-treatment
|
|
Number of Tramadol Pills Taken
Time Frame: Week 1 post-treatment
|
All patients will be discharged with 28 pills of tramadol 50mg.
At week 1 follow-up, number of tramadol pills taken will be reported.
|
Week 1 post-treatment
|
|
Number of Tramadol Pills Taken
Time Frame: Week 2 post-treatment
|
All patients will be discharged with 28 pills of tramadol 50mg.
At week 2 follow-up, number of tramadol pills taken will be reported.
|
Week 2 post-treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of cutaneous complications
Time Frame: Week 2 post-treatment
|
Cutaneous complications between immediate fracture bracing and coaptation splints in the ER within the first 2 weeks of treatment will be reported
|
Week 2 post-treatment
|
|
Score on PROMIS - Physical Function - Short Form 10b
Time Frame: Week 1 post-treatment
|
PROMIS consists of 10 statements/questions that are scored 1-5 each.
The total range of score is 10-50; a higher score indicates less difficulty performing an activity.
|
Week 1 post-treatment
|
|
Score on PROMIS - Physical Function - Short Form 10b
Time Frame: Week 2 post-treatment
|
PROMIS consists of 10 statements/questions that are scored 1-5 each.
The total range of score is 10-50; a higher score indicates less difficulty performing an activity.
|
Week 2 post-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Abhishek Ganta, MD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21-00438
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.